Radiopharmaceuticals for the palliation of painful bone metastases.
Metastatic bone pain is prevalent in advanced cancer, and, despite a plethora of available therapies, effective palliation remains a clinical challenge. Bone-seeking radiopharmaceuticals are an often-overlooked but valuable analgesic option for select patients. These agents work by binding to hydroxyapatite at the tumor-bone interface of osteoblastic lesions, delivering therapeutic doses of radiation to closely circumscribed tissue regions. They have been shown to reduce pain and improve quality of life. Their safety, simplicity, convenience of administration, and cost-effectiveness make them suitable for hospice and palliative care settings.
Reisfield
Gary M
GM
Division of Palliative Medicine, Department of Community Health and Family Medicine, University of Florida Health Science Center, Jacksonville, Florida, USA.
Silberstein
Edward B
EB
Wilson
George R
GR
D001859:Bone Neoplasms / Q000150:complications / Q000451:nursing* / Q000532:radiotherapy* / Q000556:secondary; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D015404:Nursing Methodology Research; D010148:Intractable Pain / Q000209:etiology / Q000451:nursing* / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011788:Quality of Life; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
D019275:Radiopharmaceuticals